ArticleScientific reports2026
Evaluation of cytotoxic and cellular effects of zinc nanoparticles from Saccharum officinarum (Jaggery) extract on breast cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options, making it difficult to manage effectively. This study investigates the anticancer potential of eco-friendly zinc oxide nanoparticles (SO-ZnO NPs), synthesized using Saccharum officinarum (jaggery) extract, against MDA-MB-231 breast cancer cells. The NPs were characterized by various techniques, confirming their spherical morphology, a primary particle size of 20-50 nm, aggregation into larger clusters (100-250 nm), and a moderately positive surface charge. The composition was predominantly zinc (96.1%), oxygen (2.3%), and carbon (1.59%), attributed to bioorganic capping agents. SO-ZnO NPs showed significant anticancer effects, with an IC50 of 125.00 ± 2.60 µg/mL, indicating potent cytotoxicity above this concentration. They also suppressed key inflammatory markers (IL-6 secretion and mRNA expression) and inhibited the proliferation of cancer stem cells. Notably, SO-ZnO NPs downregulated stemness markers (NANOG, OCT4, CD44) and disrupted mammosphere formation, suggesting a potential to target cancer stem cell self-renewal and modulate the tumor microenvironment. These findings underline the therapeutic potential of SO-ZnO NPs in treating TNBC, though further in vivo studies are necessary to evaluate their safety and clinical effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.